Machine Learning as a Precision-Medicine Approach to Prescribing COVID-19 Pharmacotherapy with Remdesivir or Corticosteroids

[1]  M. Gianfrancesco,et al.  Characteristics and Outcomes of People With Gout Hospitalized Due to COVID‐19: Data From the COVID‐19 Global Rheumatology Alliance Physician‐Reported Registry , 2022, ACR open rheumatology.

[2]  Jennifer Abbasí.  Younger Adults Caught in COVID-19 Crosshairs as Demographics Shift. , 2020, JAMA.

[3]  Cameron T. Nutt,et al.  New Perspectives on Antimicrobial Agents: Remdesivir Treatment for COVID-19 , 2020, Antimicrobial Agents and Chemotherapy.

[4]  Ahmed Elshafie,et al.  Efficacy and safety of remdesivir in hospitalized Covid‐19 patients: Systematic review and meta‐analysis including network meta‐analysis , 2020, Reviews in medical virology.

[5]  B. Thompson,et al.  Dexamethasone in hospitalised patients with COVID-19: addressing uncertainties , 2020, The Lancet Respiratory Medicine.

[6]  J. Vincent,et al.  Corticosteroids in severe COVID-19: a critical view of the evidence , 2020, Critical Care.

[7]  Anil M. Tharappel,et al.  Targeting Crucial Host Factors of SARS-CoV-2 , 2020, ACS infectious diseases.

[8]  S. Raut,et al.  Remdesivir: A potential game-changer or just a myth? A systematic review and meta-analysis☆ , 2020, Life Sciences.

[9]  Reed J. D. Sorensen,et al.  Modeling COVID-19 scenarios for the United States , 2020, Nature Medicine.

[10]  R. Toledano,et al.  High versus standard doses of corticosteroids in severe COVID-19: a retrospective cohort study , 2020, European Journal of Clinical Microbiology & Infectious Diseases.

[11]  R. Malekzadeh,et al.  Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results , 2020, medRxiv.

[12]  Zhènglì Shí,et al.  Characteristics of SARS-CoV-2 and COVID-19 , 2020, Nature Reviews Microbiology.

[13]  T. Wilt,et al.  Remdesivir for Adults With COVID-19 , 2020, Annals of Internal Medicine.

[14]  C. S. Kow,et al.  Quality of adverse event reporting in clinical trials of remdesivir in patients with COVID-19 , 2020, European journal of clinical pharmacology.

[15]  A. Gundlapalli,et al.  Changing Age Distribution of the COVID-19 Pandemic — United States, May–August 2020 , 2020, MMWR. Morbidity and mortality weekly report.

[16]  M. Diamond,et al.  Accelerated Preclinical Paths to Support Rapid Development of COVID-19 Therapeutics , 2020, Cell Host & Microbe.

[17]  Seyed Aghil Hooshmand,et al.  A multimodal deep learning-based drug repurposing approach for treatment of COVID-19 , 2020, Molecular Diversity.

[18]  F. Cadegiani.  Repurposing existing drugs for COVID-19: an endocrinology perspective , 2020, BMC Endocrine Disorders.

[19]  M. Peiris,et al.  What can we expect from first-generation COVID-19 vaccines? , 2020, The Lancet.

[20]  J. Rello,et al.  Steroids and COVID-19: We Need a Precision Approach, Not One Size Fits All. , 2020, Infectious diseases and therapy.

[21]  Jiayang Chen,et al.  Artificial Intelligence for COVID-19: Rapid Review , 2020, Journal of medical Internet research.

[22]  T. Rice,et al.  Corticosteroids in COVID-19 ARDS: Evidence and Hope During the Pandemic. , 2020, JAMA.

[23]  Arthur S Slutsky,et al.  Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. , 2020, JAMA.

[24]  S. Cannavò,et al.  What we have to know about corticosteroids use during Sars-Cov-2 infection , 2020, Journal of Endocrinological Investigation.

[25]  Jennifer Collins,et al.  Artificial Intelligence for COVID-19 Drug Discovery and Vaccine Development , 2020, Frontiers in Artificial Intelligence.

[26]  Rampi Ramprasad,et al.  Screening of Therapeutic Agents for COVID-19 Using Machine Learning and Ensemble Docking Studies , 2020, The journal of physical chemistry letters.

[27]  A. Koyanagi,et al.  Efficacy of Corticosteroids in Patients with SARS, MERS and COVID-19: A Systematic Review and Meta-Analysis , 2020, Journal of clinical medicine.

[28]  G. Durrieu,et al.  Hepatic Disorders With the Use of Remdesivir for Coronavirus 2019 , 2020, Clinical Gastroenterology and Hepatology.

[29]  Milena Anđelković,et al.  An overview of the safety assessment of medicines currently used in the COVID-19 disease treatment , 2020, Food and Chemical Toxicology.

[30]  Maciej Banach,et al.  Cytokine Storm in COVID-19—Immunopathological Mechanisms, Clinical Considerations, and Therapeutic Approaches: The REPROGRAM Consortium Position Paper , 2020, Frontiers in Immunology.

[31]  Sanjeev Kumar Singh,et al.  Shape-based Machine Learning Models for the potential Novel COVID-19 protease inhibitors assisted by Molecular Dynamics Simulation. , 2020, Current topics in medicinal chemistry.

[32]  C. Mohanty,et al.  Application of Artificial Intelligence in COVID-19 drug repurposing , 2020, Diabetes & Metabolic Syndrome: Clinical Research & Reviews.

[33]  Jennifer L. Bell,et al.  Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report , 2020, medRxiv.

[34]  L. Dodd,et al.  Remdesivir for the Treatment of Covid-19 — Final Report , 2020, The New England journal of medicine.

[35]  A. Gumel,et al.  Will an imperfect vaccine curtail the COVID-19 pandemic in the U.S.? , 2020, Infectious Disease Modelling.

[36]  M. Piris,et al.  Survival study of hospitalised patients with concurrent COVID‐19 and haematological malignancies , 2020, British journal of haematology.

[37]  L. Trupin,et al.  Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry , 2020, Annals of the Rheumatic Diseases.

[38]  Yi Wang,et al.  Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial , 2020, The Lancet.

[39]  N. Uriel,et al.  COVID-19 in solid organ transplant recipients: Initial report from the US epicenter , 2020, American Journal of Transplantation.

[40]  E. Akalin,et al.  Covid-19 and Kidney Transplantation , 2020, The New England journal of medicine.

[41]  R. Gale,et al.  COVID-19 in persons with haematological cancers , 2020, Leukemia.

[42]  Jiang Xie,et al.  Association Between Hypoxemia and Mortality in Patients With COVID-19 , 2020, Mayo Clinic Proceedings.

[43]  Soumitra Satapathi,et al.  Repurposing therapeutics for COVID-19: Rapid prediction of commercially available drugs through machine learning and docking , 2020, medRxiv.

[44]  Yonatan H. Grad,et al.  Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period , 2020, Science.

[45]  Muhammad Yasir,et al.  Corticosteroid Adverse Effects , 2019 .

[46]  P. Turnbaugh,et al.  Precision Medicine Goes Microscopic: Engineering the Microbiome to Improve Drug Outcomes. , 2019, Cell host & microbe.

[47]  Evan A. Clayton,et al.  Machine learning predicts individual cancer patient responses to therapeutic drugs with high accuracy , 2018, Scientific Reports.

[48]  S. Niemann,et al.  Pathogen-based precision medicine for drug-resistant tuberculosis , 2018, PLoS pathogens.

[49]  Scott Lundberg,et al.  A Unified Approach to Interpreting Model Predictions , 2017, NIPS.

[50]  C. Sander,et al.  Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy , 2014, Clinical Cancer Research.

[51]  S. Gabriel,et al.  Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. , 2014, Cancer discovery.

[52]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[53]  Alexander J. Smola,et al.  Neural Information Processing Systems , 1997, NIPS 1997.